Immunome's Groundbreaking Presentation on ADC Therapy
Today, Immunome, Inc. (Nasdaq: IMNM) is excited to announce its participation in a prominent oncology symposium where it will showcase the preclinical evaluation of IM-1021, a ROR1-targeted antibody drug conjugate (ADC). This innovative therapeutic approach could pave the way for enhanced cancer treatments, leveraging Immunome's expertise in targeted cancer therapies.
What is IM-1021?
IM-1021 is designed to target the receptor tyrosine kinase ROR1, which plays a critical role in the survival and proliferation of cancer cells. By utilizing a sophisticated drug conjugate technology, Immunome aims to deliver potent anti-cancer agents directly to tumor cells while minimizing damage to healthy tissue. This targeted strategy is central to the ongoing development of next-generation cancer therapies.
Anticipated FDA Submission
Immunome expects to submit an Investigational New Drug (IND) application for the IM-1021 program to the FDA in the near future. This proactive step is part of the company’s commitment to bringing new treatment options to patients battling cancer. By working within the stringent regulatory framework, Immunome aims to ensure the safety and efficacy of its innovative therapies.
Details of the Presentation
The poster presentation will be held at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Immunome's team is eager to share their findings with fellow researchers and industry professionals, highlighting the significance of their work in advancing ADCs.
Poster Presentation Specifics
Here are the key details regarding the presentation:
Title: Preclinical evaluation of IM-1021, a ROR1-targeted antibody-drug conjugate with a novel topoisomerase I linker payload.
Presenter: Robert Lawrence, Director of Biology, Immunome
Date: Upcoming symposium date
Understanding Immunome, Inc.
As a clinical-stage oncology company, Immunome is committed to developing cutting-edge therapies designed to improve patient outcomes in cancer treatment. The leadership team brings substantial expertise from successful roles in the design and commercialization of advanced targeted therapies, particularly antibody-drug conjugates (ADCs).
Within its diverse pipeline, Immunome boasts not only IM-1021, but also AL102, a gamma secretase inhibitor currently in a Phase 3 trial for desmoid tumors, and IM-3050, a radioligand targeting fibroblast activation protein (FAP). Both of these candidates are under INDs expected to be submitted soon.
Looking Ahead
Immunome's ongoing research signifies a commitment to innovation and excellence in the field of oncology. The company’s aim is to harness the power of targeted therapies to transform cancer care. As advancements continue, stakeholders are watching closely to see how these innovative approaches will reshape the landscape of cancer treatment.
Frequently Asked Questions
What is the significance of IM-1021?
IM-1021 represents a novel approach to cancer therapy by targeting ROR1, potentially improving the precision and effectiveness of treatment.
When will Immunome submit its IND application?
The IND for the IM-1021 program is anticipated to be submitted in the first quarter of 2025.
Who will present the research at the symposium?
Robert Lawrence, the Director of Biology at Immunome, will be presenting the findings.
Where will the poster be available after the presentation?
A copy of the poster will be uploaded to Immunome's website in the “Events & Presentations” section.
What are Immunome's future plans?
Immunome plans to continue advancing its pipeline of targeted therapies, focusing on both regulatory submissions and clinical trials to enhance cancer treatment options.
